Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Sep 2025 value amounting to -$22.2 million.

  • Ironwood Pharmaceuticals' Total Non-Current Liabilities rose 44.14% to -$22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 44.14%. This contributed to the annual value of -$17.1 million for FY2024, which is 39.80% up from last year.
  • Ironwood Pharmaceuticals' Total Non-Current Liabilities amounted to -$22.2 million in Q3 2025, which was up 1.10% from -$22.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at -$1.5 million during Q2 2021, with a 5-year trough of -$39.8 million in Q3 2024.
  • For the 3-year period, Ironwood Pharmaceuticals' Total Non-Current Liabilities averaged around -$25.9 million, with its median value being -$28.4 million (2023).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 478.86% in 2022, then soared by 44.14% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Total Non-Current Liabilities stood at -$3.5 million in 2021, then crashed by 178.95% to -$9.8 million in 2022, then tumbled by 190.96% to -$28.4 million in 2023, then spiked by 39.80% to -$17.1 million in 2024, then surged by 44.14% to -$22.2 million in 2025.
  • Its Total Non-Current Liabilities stands at -$22.2 million for Q3 2025, versus -$22.5 million for Q2 2025 and -$17.3 million for Q1 2025.